Fact sheet: BB Biotech

Fund information
Fund name
BB Biotech B USD
Fund manager company
Bellevue Asset Management
Fund type
Offshore Fund
Fund managers
  • Felicia Flanigansince 31/08/2011
  • Dallas Webbsince 31/08/2011
  • Dr.Tazio Stornisince 31/08/2011
  • Dr.. Daniel Kollersince 31/03/2009
  • Lydia Bänzigersince 02/01/2012
Fund objective
The Fund invests worldwide in companies active in the biotechnology sector. Experienced sector specialists focus on profitable mid- and large-cap companies with an established product portfolio. Stock selection is based on fundamental analysis, in particular of the medical indications addressed, the means of efficacy and the market potential. A global network of experts spanning scientific and industrial fields supports the Management Team in forming opinions and making investment decisions. The selection of portfolio companies is entirely bottom-up, independent of benchmark weightings.
Benchmark
  • NASDAQ Biotechnology
Investment style
Active,Growth
Investment method
Shares
Quick stats
1 Year return
-11.9%
1 Year rank in sector
28/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Fund size
£61m (£98m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
186
Top in this sector
Fund name1 Year
Variopartner SICAV MVGbMdtcF21.1%
Fidelity Gbl Health Care19.2%
BB Medtech18.1%
Atlantis China Healthcare13.5%
Charlemagne MagnaBiphrm12.3%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA96.5%
    Money Market2.3%
    International1.2%
  • Health Care50.9%
    Pharmaceuticals14.9%
    Others14.7%
    Healthcare & Medical Products12.5%
    Biotechnology/Medical4.7%
  • US Equities96.5%
    Money Market2.3%
    International Equities1.2%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund1.2%16.7%18.2%-11.9%36.1%197.9%
Sector1.5%10.5%12.9%-2.3%43.4%140.6%
Rank within sector13 / 329 / 3210 / 3128 / 3118 / 245 / 24
Quartile2nd2nd2nd4th3rd1st
Calendar performance
 YTD - 20162015201420132012
Fund-13%7.6%36.3%63.8%31.5%
Sector-2.4%7.2%28.1%41%16.7%
Rank within sector30 / 3117 / 299 / 264 / 243 / 24
Quartile4th3rd2nd1st1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-6.48
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.59
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.29
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
27.33
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
14
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-0.09
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.87
Price movement
52 week high496.72
52 week low340.46
Current bid price-
Current offer price-
Current mid price426.37
Region
1USA96.5%
2Money Market2.3%
3International1.2%
Industry sector
1Health Care50.9%
2Pharmaceuticals14.9%
3Others14.7%
4Healthcare & Medical Products12.5%
5Biotechnology/Medical4.7%
6Money Market2.3%
Asset type
1US Equities96.5%
2Money Market2.3%
3International Equities1.2%
Individual holdings
1BIOGEN INC7.6%
2CELGENE CORP7.2%
3REGENERON PHARMACEUTICALS INC6.9%
4AMGEN INC6.8%
5GILEAD SCIENCES INC5.7%
6ILLUMINA INC4.7%
7VERTEX PHARMACEUTICAL4.4%
8INCYTE CORP3.9%
9BIOMARIN PHARMACEUTICAL3.3%
Management
Fund manager group
Bellevue Asset Management
Fund manager company
Bellevue Asset Management
Fund type
Offshore Fund
Fund objective
The Fund invests worldwide in companies active in the biotechnology sector. Experienced sector specialists focus on profitable mid- and large-cap companies with an established product portfolio. Stock selection is based on fundamental analysis, in particular of the medical indications addressed, the means of efficacy and the market potential. A global network of experts spanning scientific and industrial fields supports the Management Team in forming opinions and making investment decisions. The selection of portfolio companies is entirely bottom-up, independent of benchmark weightings.
Benchmark
  • NASDAQ Biotechnology
Investment style
Active,Growth
Investment method
Shares
Fund managers
NameSinceBiography
Felicia Flanigan31/08/2011Felicia Flanigan has been working for Bellevue Asset Management as senior biotech analyst and Head Bellevue Research since 2006. She was previously employed as an equity analyst at Adams, Harkness & Hill and at the same position at SG Cowen. She received her MBA at Suffolk University in Boston and graduated from Boston College with a BA in Communications.
Dallas Webb31/08/2011Dallas Webb has been working as an analyst and portfolio manager for Biotec since 2006. He was previously employed as an equity analyst and senior vice president at Standford Group Company. From 2003-2004 working for Sterling Financial Investment Group also as an equity analyst and from 2002-2003 at Adams, Harkness & Hil, as a vice president, equity analyst. He received his MBA at Texas Christian University and previously studied BA in Microbiology and Zoology at Louisiana State University.
Dr.Tazio Storni31/08/2011Dr.Tazio Storni joined Bellevue Asset Management AG Management Team in 2011. He was employed at UBS Global Asset Management as a financial analyst and healthcare fund manager between 2005-2011. In 2003 took a position as a postdoctoral fellow at University Hospital Zurich. Previous studies in biotechnology at Swiss Federal Institute of Technology (ETH) Zurich PhD/doctorate in Immunology, Swiss Federal Institute of Technology (ETH) Zurich and Cytos Biotechnology Ltd, Zurich.
Dr.. Daniel Koller31/03/2009Dr. Daniel Koller joined Bellevue Asset Management as co-head biotech, lead portfolio manager of the BB Biotech (Lux) Fund and co-head BB BIOTECH Ltd in 2004. Prior to this he worked as an Investment Manager in Equity4life Asset Management Ltd from 2001-2004. Earlier he was an Equity analyst in UBS Warburg from 2000-2001. He holds a Master's degree in Biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich & a PhD in Biotechnology of the Swiss Federal Institute of Technology (ETH) Zurich and Cytos Biotechnology Ltd, Zurich.
Lydia Bänziger02/01/2012Lydia Bänziger has been working as a Research Analyst at Bellevue Asset Management since 2011. She finished Master of Science at ETH Zürich in Systems Biology in 2011 with distinction.
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Reporting Fund Status, UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Austria, Switzerland, Germany, Spain, United Kingdom, Luxembourg, Offshore
BB Biotech B CHF
Initial charge5%
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)2.3%
Bid price-
Offer price-
Mid price361.48
CurrencyCHF
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTT4
BB Biotech B EUR
Initial charge5%
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)2.3%
Bid price-
Offer price-
Mid price506.13
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTT3
BB Biotech B USD
Initial charge5%
Annual charge1.6%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)2.33%
Bid price-
Offer price-
Mid price426.37
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeGTT2
BB Biotech I CHF
Initial charge5%
Annual charge0.9%
Min single investment£500,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.56%
Bid price-
Offer price-
Mid price384.21
CurrencyCHF
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGTT6
BB Biotech I EUR
Initial charge5%
Annual charge0.9%
Min single investment£500,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.55%
Bid price-
Offer price-
Mid price537.03
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGTT7
BB Biotech I GBP
Initial charge5%
Annual charge0.9%
Min single investment£500,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)1.55%
Bid price-
Offer price-
Mid price363.67
CurrencyGBP
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi code10KL
BB Biotech I USD
Initial charge5%
Annual charge0.9%
Min single investment£500,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)-
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price450.74
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGTT5
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.